Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Am J Transplant. 2018 Dec 15;19(6):1671–1683. doi: 10.1111/ajt.15175

Table 2.

Baseline DSA and Crossmatch Testing

Variable Eculizumab-Treated +XM Patients (n=30) +XM Control Patients (n=48) P Value Eculizumab vs +XM Control Patients
Baseline B-cell flow cytometric crossmatch, mean (SD) 306 (92) 323 (78) .35
Class I DSA only, No. (%) 11 (36.7) 19 (39.5)
Class II DSA only, No. (%) 9 (30.0) 12 (25.0)
Both class I + II DSA, No. (%) 10 (33.3) 17 (35.4) .89
Anti-A specificity, No. (%) 17 (56.7) 24 (50.0) .57
Anti-B specificity, No. (%) 17 (56.7) 20 (41.7) .20
Anti-DR specificity, No. (%) 13 (43.3) 18 (37.5) .61
Anti-DQ specificity, No. (%) 12 (40.0) 20 (41.7) .88
Sum class I DSA MFI, mean (SD) 4,193.3 (4,889.0) 4,556.68 (5,083.0) .76
Sum class II DSA MFI, mean (SD) 4,037.07 (5,183.3) 3,128 (4,141.2) .40
Sum of class I and class II DSA MFI, mean (SD) 11,905.0 (8,985.3) 9,592.5 (7,806.2) .24
Number of DSA per patient, mean (SD) 2.2 (1.0) 2.6 (1.4) 0.12
Pretransplant plasmapheresis, No. (%) 17 (56.7) 32 (66.7) .52
Number of pretransplant plasmapheresis treatments, mean (SD) 4.6 (1.3) 4.4 (1.4) .78
IgG3+ (n=15), No. (%) 8 (53.3) NA
C1q+ (n=18), No. (%) 14 (77.8) NA

Abbreviations: DSA, donor-specific antibody; IgG, immunoglobulin G; MFI, mean fluorescence intensity; NA, not applicable; −XM, negative crossmatch; +XM, positive crossmatch.